Bioplatforms in liquid biopsy: advances in the techniques for isolation, characterization and clinical applications. Issue 2 (3rd July 2022)

• Record Type: Journal Article
• Authors: Shah, Ushma Jaykamal; Alsulimani, Ahmad; Ahmad, Faraz; Mathkor, Darin Mansor; Alsaieedi, Ahdab; Harakeh, Steve; Nasiruddin, Mohammad; Haque, Shafiul
• Is Part Of: Biotechnology and genetic engineering reviews. Volume 38:Issue 2(2022)
• Page Start: 339
• Page End: 383
• Publication Date: 2022-07-03
• Subjects: Liquid biopsy -- circulating tumor DNA (ctDNA) -- cell-free DNA (cfDNA) -- circulating tumor cells (CTCs) -- exosomes -- tumor-educated platelets (TEPs); Biotechnology -- Periodicals; Genetic engineering -- Periodicals; Biochemical engineering -- Periodicals; Biomedical Engineering -- Periodicals; Environmental Microbiology -- Periodicals; Genetic Engineering -- Periodicals; Microbiological Techniques -- Periodicals; Technology -- Periodicals; Periodicals; 660.605
• DOI: 10.1080/02648725.2022.2108994
• Languages: English
• ISSNs: 0264-8725

Abstract

ABSTRACT: Tissue biopsy analysis has conventionally been the gold standard for cancer prognosis, diagnosis and prediction of responses/resistances to treatments. The existing biopsy procedures used in clinical practice are, however, invasive, painful and often associated with pitfalls like poor recovery of tumor cells and infeasibility for repetition in single patients. To circumvent these limitations, alternative non-invasive, rapid and economical, yet sturdy, consistent and dependable, biopsy techniques are required. Liquid biopsy is an emerging technology that fulfills these criteria and potentially much more in terms of subject-specific real-time monitoring of cancer progression, determination of tumor heterogeneity and treatment responses, and specific identification of the type and stages of cancers. The present review first briefly revisits the state-of-the-art technique of liquid biopsy and then proceeds to address in detail, the advances in the potential clinical applications of four major biological agencies present in liquid biopsy samples (circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), exosomes and tumor-educated platelets (TEPs)). Finally, the authors conclude with the limitations that need to be addressed in order for liquid biopsy to effectively replace the conventional invasive biopsy methods in the clinical settings.